

Advanced Oncotherapy PLC

02:24 27 Sep 2018

Advanced Oncotherapy passes key technological milestone

Advanced Oncotherapy PLC (LON:AVO) said it has passed a key technological milestone on schedule.

Researchers at the CERN facility in Geneva working on the company's LIGHT system have confirmed it is now generating proton beams with sufficient energy to treat superficial tumours.

"This announcement marks the shift from a complex - albeit well-proven - scientific and physics reality into a medical application with tangible and direct implications for patients," said chief executive Nicolas Sérandour.

"This very important step supports the confidence we have in delivering our plan and being in a position to offer a system that delivers a better outcome for patients whilst generating more value for the operators."

The results from the work to date showed the LIGHT proton beam technology comfortably treated simulated superficial tumours and marginally deeper cancers.

Healthy tissue, such as the eye and the lens, was spared because of the targeted nature of the device. Dosing was well controlled.

Next target in sight

The development team is now focused on the "relatively low-execution risk activity" of adding further accelerating modules.

This will ensure the AVO equipment can treat all indications suitable for proton therapy.

"A further technical update will be provided in the next few days," the company said.

LIGHT stands for Linac Image Guided Hadron Technology. The AVO kit is cheaper and smaller than the current units, which are almost prohibitively expensive.


It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the 'God particle'.

Price: 45p

Market Cap: £90.19M

1 Year Share Price Graph



June 2018 December 2018 June 2019

Share Information

Code: AVO

Listing: LSE

52 week High Low
60.00p 33.00p

Sector: Health Care, Equipment & Services

Website: www.avopl.com

Company Synopsis:

Advanced Oncotherapy is a specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, which is the result of 25 years of work at CERN and ADAM. Our focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient's healthy tissues.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.